



## Clinical trial results:

**A randomised, double-blind, placebo controlled, parallel group comparison study to evaluate the efficacy and safety of Paxil® Tablets in children and adolescents with Major Depressive Disorder- MRP**

### Summary

|                          |                  |
|--------------------------|------------------|
| EudraCT number           | 2015-004905-17   |
| Trial protocol           | Outside EU/EEA   |
| Global end of trial date | 21 February 2011 |

### Results information

|                                |                  |
|--------------------------------|------------------|
| Result version number          | v1 (current)     |
| This version publication date  | 01 December 2016 |
| First version publication date | 01 December 2016 |

### Trial information

#### Trial identification

|                       |        |
|-----------------------|--------|
| Sponsor protocol code | 112487 |
|-----------------------|--------|

#### Additional study identifiers

|                                    |   |
|------------------------------------|---|
| ISRCTN number                      | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN)   | - |

Notes:

### Sponsors

|                              |                                                            |
|------------------------------|------------------------------------------------------------|
| Sponsor organisation name    | GlaxoSmithKline                                            |
| Sponsor organisation address | 980 Great West Road, Brentford, Middlesex, United Kingdom, |
| Public contact               | GSK Response Center, GlaxoSmithKline, 1 866-435-7343,      |
| Scientific contact           | GSK Response Center, GlaxoSmithKline, 1 866-435-7343,      |

Notes:

### Paediatric regulatory details

|                                                                      |     |
|----------------------------------------------------------------------|-----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No  |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No  |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

---

**Results analysis stage**

|                                                      |               |
|------------------------------------------------------|---------------|
| Analysis stage                                       | Final         |
| Date of interim/final analysis                       | 13 April 2011 |
| Is this the analysis of the primary completion data? | No            |

|                                  |                  |
|----------------------------------|------------------|
| Global end of trial reached?     | Yes              |
| Global end of trial date         | 21 February 2011 |
| Was the trial ended prematurely? | No               |

Notes:

---

**General information about the trial**

Main objective of the trial:

TBD

Protection of trial subjects:

Not applicable

Background therapy: -

Evidence for comparator: -

|                                                           |               |
|-----------------------------------------------------------|---------------|
| Actual start date of recruitment                          | 10 March 2009 |
| Long term follow-up planned                               | No            |
| Independent data monitoring committee (IDMC) involvement? | No            |

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

|                                      |           |
|--------------------------------------|-----------|
| Country: Number of subjects enrolled | Japan: 56 |
| Worldwide total number of subjects   | 56        |
| EEA total number of subjects         | 0         |

Notes:

---

**Subjects enrolled per age group**

|                                           |    |
|-------------------------------------------|----|
| In utero                                  | 0  |
| Preterm newborn - gestational age < 37 wk | 0  |
| Newborns (0-27 days)                      | 0  |
| Infants and toddlers (28 days-23 months)  | 0  |
| Children (2-11 years)                     | 5  |
| Adolescents (12-17 years)                 | 51 |
| Adults (18-64 years)                      | 0  |
| From 65 to 84 years                       | 0  |
| 85 years and over                         | 0  |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

This study consisted of 3 phases: a 2-week placebo run-in phase, an 8-week treatment phase, and a 0- to 3-week taper phase. In the run-in phase, placebo was administered once daily for 2 weeks. In the treatment phase, paroxetine or placebo was orally administered once daily for 8 weeks. In the taper phase, the dose was gradually reduced.

### Period 1

|                              |                                        |
|------------------------------|----------------------------------------|
| Period 1 title               | Overall Study (overall period)         |
| Is this the baseline period? | Yes                                    |
| Allocation method            | Randomised - controlled                |
| Blinding used                | Double blind                           |
| Roles blinded                | Subject, Investigator, Carer, Assessor |

### Arms

|                              |         |
|------------------------------|---------|
| Are arms mutually exclusive? | Yes     |
| <b>Arm title</b>             | Placebo |

Arm description:

Participants took placebo once daily in the treatment phase (8 weeks) and the taper phase (0 to 3 weeks).

|                                        |                                     |
|----------------------------------------|-------------------------------------|
| Arm type                               | Placebo                             |
| Investigational medicinal product name | Matched placebo to Paroxetine 20 mg |
| Investigational medicinal product code |                                     |
| Other name                             |                                     |
| Pharmaceutical forms                   | Tablet                              |
| Routes of administration               | Oral use                            |

Dosage and administration details:

1 tablet once a day after evening meal

|                                        |                                     |
|----------------------------------------|-------------------------------------|
| Investigational medicinal product name | Matched placebo to Paroxetine 10 mg |
| Investigational medicinal product code |                                     |
| Other name                             |                                     |
| Pharmaceutical forms                   | Tablet                              |
| Routes of administration               | Oral use                            |

Dosage and administration details:

2 tablets once a day after evening meal

|                  |            |
|------------------|------------|
| <b>Arm title</b> | Paroxetine |
|------------------|------------|

Arm description:

Paroxetine at the initial dose of 10 milligrams (mg) was orally administered once daily for the first 2 weeks of the treatment phase (total of 8 weeks). During the next 6 weeks, paroxetine 10 to 20 mg for participants aged 7 to 11 years or 10 to 40 mg for participants aged 12 to 17 years was orally administered. The dose was up-titrated by one level at a time (an increment of 10 mg/day) at intervals of at least 2 weeks based on clinical judgment. During the taper phase, (0 to 3 weeks), the last dose level in the treatment phase was reduced by 10 mg/day at intervals of 1 week to the final dose level of 10 mg/day.

|          |              |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

|                                        |                  |
|----------------------------------------|------------------|
| Investigational medicinal product name | Paroxetine 10 mg |
| Investigational medicinal product code |                  |
| Other name                             |                  |
| Pharmaceutical forms                   | Tablet           |
| Routes of administration               | Oral use         |

Dosage and administration details:

1 or 2 tablets once daily after evening meal

|                                        |                  |
|----------------------------------------|------------------|
| Investigational medicinal product name | Paroxetine 20 mg |
| Investigational medicinal product code |                  |
| Other name                             |                  |
| Pharmaceutical forms                   | Tablet           |
| Routes of administration               | Oral use         |

Dosage and administration details:

1 tablet once a day after evening meal

| <b>Number of subjects in period 1</b> | Placebo | Paroxetine |
|---------------------------------------|---------|------------|
| Started                               | 27      | 29         |
| Completed                             | 24      | 25         |
| Not completed                         | 3       | 4          |
| Consent withdrawn by subject          | -       | 2          |
| Adverse event, non-fatal              | 2       | 1          |
| Lost to follow-up                     | -       | 1          |
| Lack of efficacy                      | 1       | -          |

## Baseline characteristics

### Reporting groups

|                       |         |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

Reporting group description:

Participants took placebo once daily in the treatment phase (8 weeks) and the taper phase (0 to 3 weeks).

|                       |            |
|-----------------------|------------|
| Reporting group title | Paroxetine |
|-----------------------|------------|

Reporting group description:

Paroxetine at the initial dose of 10 milligrams (mg) was orally administered once daily for the first 2 weeks of the treatment phase (total of 8 weeks). During the next 6 weeks, paroxetine 10 to 20 mg for participants aged 7 to 11 years or 10 to 40 mg for participants aged 12 to 17 years was orally administered. The dose was up-titrated by one level at a time (an increment of 10 mg/day) at intervals of at least 2 weeks based on clinical judgment. During the taper phase, (0 to 3 weeks), the last dose level in the treatment phase was reduced by 10 mg/day at intervals of 1 week to the final dose level of 10 mg/day.

| Reporting group values                        | Placebo | Paroxetine | Total |
|-----------------------------------------------|---------|------------|-------|
| Number of subjects                            | 27      | 29         | 56    |
| Age categorical<br>Units: Subjects            |         |            |       |
| Age continuous                                |         |            |       |
| Age continuous description                    |         |            |       |
| Units: years                                  |         |            |       |
| arithmetic mean                               | 14.8    | 14.4       |       |
| standard deviation                            | ± 2.62  | ± 1.99     | -     |
| Gender categorical                            |         |            |       |
| Gender categorical description                |         |            |       |
| Units: Subjects                               |         |            |       |
| Female                                        | 18      | 16         | 34    |
| Male                                          | 9       | 13         | 22    |
| Race/Ethnicity, Customized<br>Units: Subjects |         |            |       |
| Asian - Japanese Heritage                     | 27      | 29         | 56    |

## End points

### End points reporting groups

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Reporting group title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Placebo    |
| Reporting group description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |
| Participants took placebo once daily in the treatment phase (8 weeks) and the taper phase (0 to 3 weeks).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Paroxetine |
| Reporting group description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |
| Paroxetine at the initial dose of 10 milligrams (mg) was orally administered once daily for the first 2 weeks of the treatment phase (total of 8 weeks). During the next 6 weeks, paroxetine 10 to 20 mg for participants aged 7 to 11 years or 10 to 40 mg for participants aged 12 to 17 years was orally administered. The dose was up-titrated by one level at a time (an increment of 10 mg/day) at intervals of at least 2 weeks based on clinical judgment. During the taper phase, (0 to 3 weeks), the last dose level in the treatment phase was reduced by 10 mg/day at intervals of 1 week to the final dose level of 10 mg/day. |            |

### Primary: Change from Baseline in the Children's Depression Rating Scale -Revised (CDRS-R) Total Score at Week 8

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Change from Baseline in the Children's Depression Rating Scale -Revised (CDRS-R) Total Score at Week 8 |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                        |
| The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 questions. Each question is graded on a 5- or 7-point scale. The highest possible score is 113 (the most severe measure of depression), and the lowest is 17 (not suffering from depression). CDRS-R scores were assessed by the investigator. The change from Baseline in the CDRS-R total score was calculated as the total score at Week 8 minus the total score at Baseline. The data were adjusted with the total score at Baseline. Full Analysis Set (FAS): all participants who entered the treatment phase, but excluding participants without the target indication, participants who received no tablet of the treatment phase medication, or participants who had no post-baseline CDRS-R data. The analysis was performed on the last observation carried forward (LOCF) dataset. |                                                                                                        |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Primary                                                                                                |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                        |
| Baseline and Week 8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                        |

| End point values                    | Placebo           | Paroxetine        |  |  |
|-------------------------------------|-------------------|-------------------|--|--|
| Subject group type                  | Reporting group   | Reporting group   |  |  |
| Number of subjects analysed         | 27 <sup>[1]</sup> | 29 <sup>[2]</sup> |  |  |
| Units: scores on a scale            |                   |                   |  |  |
| least squares mean (standard error) | -11.9 (± 2.54)    | -16.5 (± 2.45)    |  |  |

Notes:

[1] - Full Analysis Set.

[2] - Full Analysis Set.

### Statistical analyses

|                                                            |                        |
|------------------------------------------------------------|------------------------|
| Statistical analysis title                                 | Statistical analysis 1 |
| Statistical analysis description:                          |                        |
| Mean difference was estimated as paroxetine minus placebo. |                        |

|                                         |                       |
|-----------------------------------------|-----------------------|
| Comparison groups                       | Paroxetine v Placebo  |
| Number of subjects included in analysis | 56                    |
| Analysis specification                  | Pre-specified         |
| Analysis type                           | other                 |
| P-value                                 | = 0.198               |
| Method                                  | ANCOVA                |
| Parameter estimate                      | Mean difference (net) |
| Point estimate                          | -4.6                  |
| Confidence interval                     |                       |
| level                                   | 95 %                  |
| sides                                   | 2-sided               |
| lower limit                             | -11.7                 |
| upper limit                             | 2.5                   |

## Secondary: Change from Baseline in the CDRS-R Total Score at Weeks 1, 2, 3, 4, and 6

|                 |                                                                           |
|-----------------|---------------------------------------------------------------------------|
| End point title | Change from Baseline in the CDRS-R Total Score at Weeks 1, 2, 3, 4, and 6 |
|-----------------|---------------------------------------------------------------------------|

### End point description:

The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder. The CDRS-R total score is the sum of the responses to 17 questions. Each question is graded on a 5- or 7-point scale. The highest possible score is 113 (the most severe measure of depression), and the lowest is 17 (not suffering from depression). CDRS-R scores were assessed by the investigator. The change from Baseline in the CDRS-R total score was calculated as the total score at Week 8 minus the total score at Baseline. The data were adjusted with the total score at Baseline.

The analysis was performed on the observed case dataset. Participants whose observation was missing at a particular visit were not included in the analysis for that week.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

### End point timeframe:

Baseline and Weeks 1, 2, 3, 4, and 6

| End point values                    | Placebo           | Paroxetine        |  |  |
|-------------------------------------|-------------------|-------------------|--|--|
| Subject group type                  | Reporting group   | Reporting group   |  |  |
| Number of subjects analysed         | 27 <sup>[3]</sup> | 29 <sup>[4]</sup> |  |  |
| Units: scores on a scale            |                   |                   |  |  |
| least squares mean (standard error) |                   |                   |  |  |
| Week 1, n=27, 29                    | -4.6 (± 1.1)      | -5.4 (± 1.06)     |  |  |
| Week 2, n=26, 29                    | -4.9 (± 1.56)     | -8.8 (± 1.48)     |  |  |
| Week 3, n=24, 28                    | -10.6 (± 1.9)     | -12 (± 1.76)      |  |  |
| Week 4, n=25, 27                    | -12.5 (± 2.24)    | -14.6 (± 2.15)    |  |  |
| Week 6, n=24, 26                    | -14.2 (± 2.21)    | -15.7 (± 2.12)    |  |  |

### Notes:

[3] - Full Analysis Set.

[4] - Full Analysis Set.

## Statistical analyses

No statistical analyses for this end point

---

**Secondary: Number of Clinical Global Impression - Global Improvement (CGI-GI) Responders at Weeks 1, 2, 3, 4, 6, and 8**

---

|                 |                                                                                                             |
|-----------------|-------------------------------------------------------------------------------------------------------------|
| End point title | Number of Clinical Global Impression - Global Improvement (CGI-GI) Responders at Weeks 1, 2, 3, 4, 6, and 8 |
|-----------------|-------------------------------------------------------------------------------------------------------------|

End point description:

CGI-GI is assessed on an 8-grade scale: 0, not assessed; 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse. CGI-GI was assessed by the investigator. Participants who were rated as 1 (very much improved) or 2 (much improved) were categorized as CGI-GI responders.

The analysis was performed on the OC dataset. Participants whose observation was missing at a particular visit were not included in the analysis for that week. The analysis of data at Week 8 was also performed on the LOCF dataset

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Weeks 1, 2, 3, 4, 6, and 8

---

| End point values            | Placebo           | Paroxetine        |  |  |
|-----------------------------|-------------------|-------------------|--|--|
| Subject group type          | Reporting group   | Reporting group   |  |  |
| Number of subjects analysed | 27 <sup>[5]</sup> | 29 <sup>[6]</sup> |  |  |
| Units: participants         |                   |                   |  |  |
| Week 1, n=27, 29            | 4                 | 4                 |  |  |
| Week 2, n=26, 29            | 4                 | 7                 |  |  |
| Week 3, n=24, 28            | 7                 | 9                 |  |  |
| Week 4, n=25, 27            | 13                | 12                |  |  |
| Week 6, n=24, 26            | 12                | 13                |  |  |
| Week 8 (OC), n=24, 25       | 11                | 14                |  |  |
| Week 8 (LOCF), n=27, 29     | 11                | 15                |  |  |

Notes:

[5] - Full Analysis Set.

[6] - Full Analysis Set.

---

**Statistical analyses**

---

No statistical analyses for this end point

---

---

**Secondary: Change from Baseline in the Clinical Global Impression - Severity of Illness (CGI-SI) Score at Weeks 1, 2, 3, 4, 6, and 8**

---

|                 |                                                                                                                           |
|-----------------|---------------------------------------------------------------------------------------------------------------------------|
| End point title | Change from Baseline in the Clinical Global Impression - Severity of Illness (CGI-SI) Score at Weeks 1, 2, 3, 4, 6, and 8 |
|-----------------|---------------------------------------------------------------------------------------------------------------------------|

End point description:

CGI-SI is assessed on an 8-grade scale: 0, not assessed; 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; and 7, among the most extremely ill. CGI-SI was assessed by the investigator. The change from Baseline in CGI-SI score was calculated as the score at Weeks 1, 2, 3, 4, 6, and 8 minus the score at Baseline.

The analysis was performed on the OC dataset. Participants whose observation was missing at a particular visit were not included in the analysis for that week. The analysis of data at Week 8 was also performed on the LOCF dataset.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Weeks 1, 2, 3, 4, 6, and 8

---

| End point values                     | Placebo           | Paroxetine        |  |  |
|--------------------------------------|-------------------|-------------------|--|--|
| Subject group type                   | Reporting group   | Reporting group   |  |  |
| Number of subjects analysed          | 27 <sup>[7]</sup> | 29 <sup>[8]</sup> |  |  |
| Units: scores on a scale             |                   |                   |  |  |
| arithmetic mean (standard deviation) |                   |                   |  |  |
| Week 1, n=27, 29                     | -0.1 (± 0.32)     | -0.2 (± 0.41)     |  |  |
| Week 2, n=26, 29                     | -0.1 (± 0.48)     | -0.5 (± 0.69)     |  |  |
| Week 3, n=24, 28                     | -0.3 (± 0.62)     | -0.6 (± 0.57)     |  |  |
| Week 4, n=25, 27                     | -0.5 (± 0.82)     | -0.7 (± 0.76)     |  |  |
| Week 6, n=24, 26                     | -0.5 (± 0.66)     | -0.8 (± 0.82)     |  |  |
| Week 8 (OC), n=24, 25                | -0.5 (± 0.72)     | -1 (± 0.89)       |  |  |
| Week 8 (LOCF), n=27, 29              | -0.4 (± 0.75)     | -0.9 (± 0.88)     |  |  |

Notes:

[7] - Full Analysis Set.

[8] - Full Analysis Set.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Plasma paroxetine concentrations at 12 hours and 24 hours after administration of study drug at Week 8 or Withdrawal

|                 |                                                                                                                                     |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Plasma paroxetine concentrations at 12 hours and 24 hours after administration of study drug at Week 8 or Withdrawal <sup>[9]</sup> |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Summary statistics for the plasma paroxetine concentrations at each time point were calculated by the dosage just before blood sampling using data from participants in whom plasma samples were collected at either 12 hours (plus or minus 2 hours) or 24 hours (plus or minus 2 hours) after the last administration of the study drug at Week 8 or Withdrawal (up to Week 8).

All participants who received paroxetine and in whom plasma samples were collected at either 12 hours (plus or minus 2 hours) or 24 hours (plus or minus 2 hours) after the last administration of the study drug at Week 8 or Withdrawal (up to Week 8).

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 8 or Withdrawal (up to Week 8)

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period.

| End point values                        | Paroxetine         |  |  |  |
|-----------------------------------------|--------------------|--|--|--|
| Subject group type                      | Reporting group    |  |  |  |
| Number of subjects analysed             | 18                 |  |  |  |
| Units: nanograms per milliliter (ng/mL) |                    |  |  |  |
| arithmetic mean (standard deviation)    |                    |  |  |  |
| paroxetine 10 mg, 12 hours, n=4         | 4.4683 (± 2.16507) |  |  |  |
| paroxetine 10 mg, 24 hours, n=3         | 8.9713 (± 7.81518) |  |  |  |
| paroxetine 20 mg, 12 hours, n=1         | 49.582 (± 0)       |  |  |  |

|                                 |                           |  |  |  |
|---------------------------------|---------------------------|--|--|--|
| paroxetine 20 mg, 24 hours, n=3 | 18.2713 ( $\pm$ 9.78765)  |  |  |  |
| paroxetine 30 mg, 12 hours, n=2 | 64.4285 ( $\pm$ 23.34372) |  |  |  |
| paroxetine 40 mg, 12 hours, n=3 | 108.9133 ( $\pm$ 9.01693) |  |  |  |
| paroxetine 40 mg, 24 hours, n=2 | 67.9855 ( $\pm$ 4.08778)  |  |  |  |

## Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Serious adverse events (SAEs) and non-serious AEs were collected during the treatment (8 weeks at maximum) and taper phases (3 weeks at maximum). SAEs were also collected during the follow-up phase (2 weeks after the last dose of investigational product).

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 13.1 |
|--------------------|------|

### Reporting groups

|                       |         |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

Reporting group description:

Participants took placebo once daily in the treatment phase (8 weeks) and the taper phase (0 to 3 weeks).

|                       |            |
|-----------------------|------------|
| Reporting group title | Paroxetine |
|-----------------------|------------|

Reporting group description:

Paroxetine at the initial dose of 10 mg was orally administered once daily for the first 2 weeks of the treatment phase. In the next 6 weeks, paroxetine 10 to 20 mg for participants aged 7 to 11 years or 10 to 40 mg for participants aged 12 to 17 years was orally administered. The dose was up-titrated by one level at a time (an increment of 10 mg/day) at intervals of at least 2 weeks based on clinical judgment. During the taper phase (0 to 3 weeks), the last dose level in the treatment phase was reduced by 10 mg/day at intervals of 1 week to the final dose level of 10 mg/day.

| Serious adverse events                            | Placebo        | Paroxetine     |  |
|---------------------------------------------------|----------------|----------------|--|
| Total subjects affected by serious adverse events |                |                |  |
| subjects affected / exposed                       | 0 / 27 (0.00%) | 0 / 29 (0.00%) |  |
| number of deaths (all causes)                     | 0              | 0              |  |
| number of deaths resulting from adverse events    |                |                |  |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events                            | Placebo         | Paroxetine      |  |
|-------------------------------------------------------|-----------------|-----------------|--|
| Total subjects affected by non-serious adverse events |                 |                 |  |
| subjects affected / exposed                           | 9 / 27 (33.33%) | 9 / 29 (31.03%) |  |
| Nervous system disorders                              |                 |                 |  |
| Headache                                              |                 |                 |  |
| subjects affected / exposed                           | 0 / 27 (0.00%)  | 2 / 29 (6.90%)  |  |
| occurrences (all)                                     | 0               | 2               |  |
| Reproductive system and breast disorders              |                 |                 |  |

|                                                                                                                                                                         |                                                 |                                                 |  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|--|
| Dysmenorrhoea<br>subjects affected / exposed<br>occurrences (all)                                                                                                       | 2 / 27 (7.41%)<br>2                             | 1 / 29 (3.45%)<br>1                             |  |
| Psychiatric disorders<br>Suicidal ideation<br>subjects affected / exposed<br>occurrences (all)                                                                          | 3 / 27 (11.11%)<br>3                            | 0 / 29 (0.00%)<br>0                             |  |
| Infections and infestations<br>Nasopharyngitis<br>subjects affected / exposed<br>occurrences (all)<br><br>Influenza<br>subjects affected / exposed<br>occurrences (all) | 4 / 27 (14.81%)<br>4<br><br>2 / 27 (7.41%)<br>2 | 6 / 29 (20.69%)<br>6<br><br>1 / 29 (3.45%)<br>1 |  |

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported